Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
$1.22
+13.0%
$0.70
$0.40
$2.36
$57.83M1.111.64 million shs827,774 shs
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$9.00
-2.0%
$8.58
$3.96
$9.42
$251.20M0.5864,516 shs54,916 shs
Humacyte, Inc. stock logo
HUMA
Humacyte
$1.43
-2.1%
$2.07
$1.15
$6.77
$231.22M1.875.48 million shs2.54 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$1.96
+1.6%
$2.09
$0.13
$3.29
$248.30M2.057.70 million shs3.06 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
+12.96%+4.27%+74.04%+110.71%-40.78%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-1.96%+1.47%+10.29%+6.76%+61.87%
Humacyte, Inc. stock logo
HUMA
Humacyte
-2.05%-7.74%-35.29%-44.79%-74.87%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+1.55%-0.51%-6.22%+775.78%+131.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
$1.22
+13.0%
$0.70
$0.40
$2.36
$57.83M1.111.64 million shs827,774 shs
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$9.00
-2.0%
$8.58
$3.96
$9.42
$251.20M0.5864,516 shs54,916 shs
Humacyte, Inc. stock logo
HUMA
Humacyte
$1.43
-2.1%
$2.07
$1.15
$6.77
$231.22M1.875.48 million shs2.54 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$1.96
+1.6%
$2.09
$0.13
$3.29
$248.30M2.057.70 million shs3.06 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
+12.96%+4.27%+74.04%+110.71%-40.78%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-1.96%+1.47%+10.29%+6.76%+61.87%
Humacyte, Inc. stock logo
HUMA
Humacyte
-2.05%-7.74%-35.29%-44.79%-74.87%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+1.55%-0.51%-6.22%+775.78%+131.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
2.83
Moderate Buy$3.30170.49% Upside
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
3.00
Buy$13.3348.15% Upside
Humacyte, Inc. stock logo
HUMA
Humacyte
3.00
Buy$9.75581.82% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.56
Moderate Buy$6.07209.52% Upside

Current Analyst Ratings Breakdown

Latest ALXO, VOR, FENC, and HUMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$3.50
8/27/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$3.50
8/21/2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$13.00
8/15/2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/15/2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$13.00 ➝ $14.00
8/14/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
8/12/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$5.00 ➝ $3.50
8/12/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$4.00 ➝ $3.00
8/11/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
7/23/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
7/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
N/AN/AN/AN/A$2.14 per shareN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$33.30M7.54$0.03 per share284.25($0.21) per share-42.86
Humacyte, Inc. stock logo
HUMA
Humacyte
$1.57M144.25N/AN/A($0.41) per share-3.49
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-$134.85M-$2.20N/AN/AN/AN/A-115.67%-84.82%11/6/2025 (Estimated)
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)
Humacyte, Inc. stock logo
HUMA
Humacyte
-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%11/14/2025 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$13.66N/AN/AN/AN/AN/AN/AN/A

Latest ALXO, VOR, FENC, and HUMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million
8/12/2025Q2 2025
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-$0.46-$0.49-$0.03-$0.49N/AN/A
8/11/2025Q2 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
N/AN/AN/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMA
Humacyte
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
0.11
4.52
4.52
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/A
4.85
4.59
Humacyte, Inc. stock logo
HUMA
Humacyte
2.97
2.45
1.93
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
97.97%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
55.51%
Humacyte, Inc. stock logo
HUMA
Humacyte
44.71%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
21.00%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
11.76%
Humacyte, Inc. stock logo
HUMA
Humacyte
5.10%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
4053.55 million42.31 millionOptionable
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
1027.91 million24.54 millionOptionable
Humacyte, Inc. stock logo
HUMA
Humacyte
150158.37 million150.30 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140126.68 million65.45 millionNot Optionable

Recent News About These Companies

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Vor Bio to Participate in Upcoming Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ALX Oncology stock logo

ALX Oncology NASDAQ:ALXO

$1.22 +0.14 (+12.96%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.16 -0.05 (-4.51%)
As of 09/5/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Adherex Technologies stock logo

Adherex Technologies NASDAQ:FENC

$9.00 -0.18 (-1.96%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$9.00 0.00 (0.00%)
As of 09/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Humacyte stock logo

Humacyte NASDAQ:HUMA

$1.43 -0.03 (-2.05%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.42 0.00 (-0.35%)
As of 09/5/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$1.96 +0.03 (+1.55%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.96 0.00 (0.00%)
As of 09/5/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.